Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 232 entries
View as:

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Phase: N/A Priority: Normal
NCT ID: NCT03525548 Org: User:
Start: 08/03/18 End: 12/28/18 Due: 12/28/19

A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT03304522 Org: User:
Start: 09/20/17 End: 11/08/18 Due: 11/08/19

Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT01048255 Org: User:
Start: 01/31/10 End: 11/30/10 Due: 11/30/11

Study of VX-770 and Rifampin in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01018368 Org: User:
Start: 11/30/09 End: 03/31/10 Due: 03/31/11

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06420765 Org: User:
Start: 05/21/24 End: 04/04/25 Due: 04/04/26

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Phase: N/A Priority: Normal
NCT ID: NCT04058353 Org: User:
Start: 08/28/19 End: 06/12/20 Due: 06/12/21

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT05437120 Org: User:
Start: 07/22/22 End: 03/16/23 Due: 03/16/24

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

Phase: N/A Priority: Normal
NCT ID: NCT00909532 Org: User:
Start: 06/30/09 End: 11/30/12 Due: 11/30/13

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Phase: N/A Priority: Normal
NCT ID: NCT03764072 Org: User:
Start: 12/12/18 End: 01/25/19 Due: 01/25/20

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Phase: N/A Priority: Normal
NCT ID: NCT03277196 Org: User:
Start: 08/16/17 End: 10/02/23 Due: 10/02/24

Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01888393 Org: User:
Start: 06/30/13 End: 11/30/13 Due: 11/30/14

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Phase: N/A Priority: Normal
NCT ID: NCT02347657 Org: User:
Start: 01/31/15 End: 01/20/17 Due: 01/20/18

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02875366 Org: User:
Start: 09/30/16 End: 10/31/17 Due: 10/31/18

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04043806 Org: User:
Start: 08/09/19 End: 12/14/22 Due: 12/14/23

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Phase: N/A Priority: Normal
NCT ID: NCT02953314 Org: User:
Start: 11/30/16 End: 09/30/18 Due: 09/30/19

A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06615570 Org: User:
Start: 09/30/24 End: 10/31/25 Due: 10/31/26

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

Phase: N/A Priority: Normal
NCT ID: NCT02070744 Org: User:
Start: 03/31/14 End: 05/27/16 Due: 05/27/17

A Microneurography (MNG) Study of VX-150 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05418712 Org: User:
Start: 06/16/22 End: 09/23/22 Due: 09/23/23

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05076149 Org: User:
Start: 10/27/21 End: 11/30/23 Due: 11/30/24

VX-770 Expanded Access Program

Phase: N/A Priority: Normal
NCT ID: NCT01381289 Org: User:
Start: - End: - Due: -

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

Phase: N/A Priority: Normal
NCT ID: NCT01275599 Org: User:
Start: 01/31/11 End: - Due: -

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01931839 Org: User:
Start: 10/31/13 End: 04/30/16 Due: 04/30/17

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Phase: N/A Priority: Normal
NCT ID: NCT00983853 Org: User:
Start: 10/31/09 End: - Due: -

Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00789126 Org: User:
Start: 10/31/08 End: - Due: -

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01225211 Org: User:
Start: 10/31/10 End: 04/30/14 Due: 04/30/15